Phase 2 Trial of Streptozotocin by Continuous Infusion for Metastatic Colorectal Carcinoma.
Cancer drug delivery
- Publish Date: 1987
- ISSN: 0732-9482
- Volume: 4
- Issue: 1
- Pages: 43-6
- Medium: Print
- Language: English
- Citation (JAMA): Clamon G, Riggs C, Stegink L, et al. Phase 2 Trial of Streptozotocin by Continuous Infusion for Metastatic Colorectal Carcinoma.. 1987;4:43-6
Abstract
Streptozotocin is a nitrosourea with minimal activity against colorectal carcinoma when given by bolus administration. Continuous infusion (CI) streptozotocin has been reportedly less toxic. Twenty-six patients with widely advanced colorectal carcinoma (most heavily pretreated) received 1-3 courses of Streptozotocin by CI to determine efficacy. Two patients (8%) had an objective response. Although CI Streptozotocin is less toxic, it does not have substantial efficacy in colorectal cancer in previously treated patients with widespread metastases.
Mesh Headings (Keywords): Adult, Aged, Colonic Neoplasms, Drug Evaluation, Female, Humans, Liver Neoplasms, Lung Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Rectal Neoplasms, Streptozocin
Check for Full Text / PubMed Unique Identifier (PMID): 2955883
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.